Advertisement
Canada markets open in 3 hours 54 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7325
    +0.0002 (+0.02%)
     

  • CRUDE OIL

    83.84
    +0.27 (+0.32%)
     

  • Bitcoin CAD

    88,117.49
    +747.04 (+0.86%)
     

  • CMC Crypto 200

    1,390.83
    -5.70 (-0.41%)
     

  • GOLD FUTURES

    2,361.60
    +19.10 (+0.82%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,715.25
    +147.75 (+0.84%)
     

  • VOLATILITY

    15.68
    +0.31 (+2.02%)
     

  • FTSE

    8,110.62
    +31.76 (+0.39%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6822
    +0.0001 (+0.01%)
     

Pfizer Gets FDA Approval for Biosimilar of AbbVie's Humira

Zacks Equity Research

Pfizer, Inc. PFE announced that the FDA granted approval to its biosimilar version of AbbVie’s ABBV blockbuster drug Humira for multiple inflammatory conditions. The biosimilar will be marketed by the trade name Abrilada.

Pfizer has a non-exclusive licensing deal with AbbVie under which it can launch Abrilada in the United States on Nov 20, 2023. In the EU, Pfizer can launch Humira biosimilar when it gets an approval from the European Medicines Agency.

The FDA nod was based on a comprehensive data package, which included results from the REFLECTIONS B538-02 comparative study. The study found no clinically meaningful differences in the efficacy, safety or immunogenicity of Abrilada to AbbVie’s branded product.

Pfizer’s shares have declined 14.8% this year so far versus its industry’s increase of 4.7%.

ADVERTISEMENT

 

 

The approval of Humira biosimilar is the fourth U.S. nod to a biosimilar product for Pfizer in 2019. Earlier this year, the company’s biosimilar versions of Roche’s RHHBY cancer drugs Herceptin (trade name: Trazimera), Avastin (trade name: Zirabev) and Rituxan (trade name: Ruxience) were approved by the FDA. Biosimilars of Herceptin and Avastin are already approved in the EU while that of Rituxan is under review in the region. In Europe and the United States, Pfizer also markets biosimilar versions of Amgen’s AMGN drugs Neupogen and Epogen and Merck/J&J’s Remicade.

Humira is AbbVie’s key top-line driver. Several companies made biosimilar versions of Humira. Including Pfizer, AbbVie has settled with nine manufacturers, per which,       Humira biosimilars are expected to be launched in the United States during 2023. However, Humira biosimilars are already launched in Europe.

Pfizer currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replac-ed by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

See 8 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
AbbVie Inc. (ABBV) : Free Stock Analysis Report
 
Roche Holding AG (RHHBY) : Free Stock Analysis Report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
Amgen Inc. (AMGN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research